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Abstract
Magnetic resonance imaging (MRI) is a non-invasive diagnostic methodology used to provide a
two-dimensional view of an internal organ or structure, especially the brain and spinal cord. Magnetic
resonance contrast agents are usually injected into necessary parts of the body prior to imaging to
increase the differences between different tissues or between normal and abnormal tissue, making it
easier for a radiologist or doctor to interpret the image that is taken. The development of new and more
efficient, effective, and selective contrast agents for various biological processes or chemicals is a
growing field of research and study.
My project allowed me to engage in undergraduate chemistry research in an academic setting
under the supervision of an organic chemistry professor, Dr. DeBoef. He designed a molecule that will be
developed further to be a magnetic resonance contrast agent, also referred to as an MRI probe.
Reactions were carried out that were the beginning steps of the multi-step synthesis, or recipe, if you will,
to make the target molecule which also binds gadolinium, making it MRI active (Figure 1). The entire
multi-step synthesis is not included in this paper. The purpose of his design is for the molecule to
selectively bind dopamine (Figure 2), a neurotransmitter that has been found to be associated with
Parkinson’s Disease in humans. His molecule’s design is based on existing contrast agent structures
published in chemical literature but is a new molecule after changes and additions were made. It can be
years later before it will be tested for use in MRI as a contrast agent that is safe for use in humans.

Project Objective
The project’s objective was to synthesize a ligand via a 6-step synthesis that is not shown in this paper.
11
The ligand’s structure was a combination of Frullano et al.’s MRI probe and Feuster et al.’s dopamine
18
sensor . As a result, it is to be a selective dopamine binding magnetic resonance contrast agent. Figure
1 shows how it will serve as a ligand for the paramagnetic gadolinium ion as well as bind to two
molecules of dopamine.
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Figure 1. (Top) is a structural drawing of the ligand bound to Gd3+ and also to
two dopamine molecules. (Bottom) is a 3-D version of top; Large grey sphere
is the gadolinium; Red=Nitrogen; Yellow=Boron; Blue=Oxygen; Light
Blue=Hydrogen; Small Grey=Carbon; Note that one boron atom is hidden at
the bottom right of the Gd3+. Figures drawn in ChemDraw.
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Detection of Dopamine In Its Environment
(This section is written based on Reference 5.)
Scientists are attempting to directly measure dopamine levels in the brains of living organisms. This
neurotransmitter is a hot target in biochemical, chemical, and neurological research.
HO

NH2

HO

Figure 2. Dopamine
7

Dopamine is a natural messenger in the brain; it is involved in reward, motivation, and mood. It is
involved in motor and cognitive functions. Both dopamine and dopamine transporter (DAT) provide
8
markers for conditions such as Parkinson’s disease, attention deficit hyperactivity disorder (ADHD) and
schizophrenia. Deficits in dopamine cause Parkinson’s Disease in humans. The most serious loss of
dopaminergic transmission during Parkinson’s disease is in the caudate-putamen; therefore this region
5
has been associated with motor control.
5

Analytical chemists are working on electrochemical methods and sensors to detect dopamine. The brain,
however presents a challenging environment for chemical sensing due to the presence of other
compounds including dopamine metabolites, ascorbic acid, and other neurotransmitters such as
14
serotonin, nitric oxide, and norepinephrine. Rapid, selective, and sensitive measurements are critical for
5
real-time detection of chemical changes in the brain.
Figure 3 shows a dopaminergic neuron (taken from Reference 5). Neurons are cells that integrate and
control information. Depending on the circuits that they are involved in, they gather, process, and relay
specific types of information. Dopaminergic neurons are located in only a few discrete regions of the
brain, with the cell bodies found in one area, and the axons projecting in another. They contain dendrites
and axons which are projections attached to the cell body. Most cell bodies are in the substantia
nigra/ventral tegmental area and their axons project to various regions such as the caudate-putamen or
the nucleus accumbens. Projections to nucleus accumbens play a part in the brain reward circuit. There
are only ~10,000 dopaminergic neurons on each side of the brain in this pathway, but each axon can
branch and form many terminals. These regions cover only a few millimeters in their largest dimension.
Dopamine is synthesized in the neuron and then packaged into membrane-bound packets called
vesicles. See Figure 3 again. An electrical impulse called an action potential initiates release of
neurotransmitter. Each neuron has a resting membrane potential caused by ionic concentration gradients
across the cell membrane. When binding occurs between the appropriate neurotransmitter and the
receptors on the dendrites or cell body, ion channels open, initiating an action potential, or “firing.” This
action potential propagates through the axon to the terminal. Other ionic channels in the terminals are
opened, which cause the vesicles to release their contents. This releasing process is called exocytosis
and occurs on a millisecond timescale. The extracellular concentration of neurotransmitter following
exocytosis depends on the number of vesicles released as well as the amount of neurotransmitter
5
present per vesicle, which may be quite small. Retinal dopaminergic neurons are said to only contain
-21
12
10 mole quantities of dopamine. After exocytosis, dopamine rapidly diffuses out of the synaptic cleft to
interact with dopaminergic receptors. Dopamine concentrations in extracellular fluid depend on uptake
and diffusion.
Dopamine transporter (DAT) is a membrane-bound protein that pumps dopamine from the extracellular
space and controls uptake into neurons. Uptake is fast in the caudate-putamen region of the brain,
5
occurring at 4 micromoles per liter per second. Once dopamine gets transported back into the neuron, it
5
is either repackaged into vesicles or metabolized.

4
5

Dopamine is released in low concentrations and rapidly cleared from extracellular space, therefore, our
MRI probe should be developed for use in intracellular space, if possible. Measuring dopamine
5
concentrations inside the 100-nm synapse has not yet been achieved yet. Analytical chemists are
currently trying to minimize the size of the electrodes that they use to approach the synapse as well as
minimize tissue damage. Our MRI probe, if successful, would not be invasive to human tissues in this
sense.

Figure 3. Venton,
B. J. and
Wightman, R. M.
Anal. Chem. 2003,
414A-421A.
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Magnetic Resonance Imaging
(This section is based on Reference 13.)
MRI is a noninvasive imaging technique that uses magnets to create an external magnetic field and lowenergy radio frequency signals. MRI gathers information from atomic nuclei in the body, specifically
hydrogen nuclei, or protons.
The patient is submitted to a strong external magnetic field (B0). Nuclei adopt to one of two orientations to
become either parallel or anti-parallel to the external field. Parallel alignment is the lower energy state and
is the preferred alignment. See Figure 5 and 6.
The net magnetization vector (Mz) aligned to the external magnet results from the difference between the
two states, which is very small, with a population ratio of 100,000 to 100,006. Individual nuclei that do not
line up with B0 wobble or precess around the direction of the magnetic field. This precessional, or Larmor
frequency is given by equation (1).

Eq (1). From Reference 13.
Commercial systems use magnetic fields that are about 1.5 Tesla, and a Larmor frequency of 63.75 MHz
for hydrogen nuclei. Each individual nucleus has a different phase of precession around the axis of the
magnetic field. The net magnetization vector from nuclei inside a magnet in equilibrium state is static and
does not produce a measurable signal. To obtain information from spins the direction of the Mz must be
altered. Precessing spins are excited by applying energy in the form of radio frequency (RF) energy
pulses of exactly the Larmor (resonance) frequency. When the RF signal is administered into patient, two
things occur: 1) Enough protons absorb energy to jump from the lower energy parallel to higher energy
anti-parallel state; 2) Electron are whipped to precess in phase. The effect is that Mz flips 90 degrees
from positive z-axis to transverse plane. It then rotates around B0 at the Larmor frequency. This rotating
transverse Mz can be measured because it induces an AC in the receiver coil that is placed around the
patient. See Figure 7.
After the RF transmitter is switched off, the equilibrium state will be sought where the high energy
decreases to low energy. In other words, the magnetization decays over time; this is represented by a
decrease in the magnitude of Mz in the transverse plane. Consequently, the induced signal in the receiver
coil will also decrease over time. This decreasing signal is known as Free Induction Decay (FID).
Relaxation time is the time required for the signal to return to equilibrium. Two relaxation processes exist:
longitudinal relaxation and transverse relaxation. See Figure 8.They are independent of one another and
are characterized as T1 and T2 relaxation times, respectively. Longitudinal relaxation is the process of
realignment to the external magnetic field. The T1 relaxation time is the time required for the system to
recover to 63% of its equilibrium value after it has been exposed to a 90degree RF pulse. Various human
tissues have different T1 values. Transverse relaxation, also known as spin-spin relaxation, depends on
the spins precessing around the Mz vector. After excitation by RF pulse the spins initially precess
completely in phase. As time passes, the observed signal starts to decrease because the spins start to
diphase due to small differences in the Larmor frequency induced by random local magnetic
inhomogeneities, spin-spin interactions, and inhomogeneity of the main static magnetic field, B0. T2
relaxation time is the time it takes for dephasing to decay the signal to 37% of its value. T2 time is
different for various tissues but is always shorter than T1.
MRI has the potential to visualize the difference in T1 and T2 of different tissues. Using these differences,
15
contrast between different soft tissues in MRI is superb compared with x-ray computer tomography. See

6
Figure 4 for different MRI images of the brain that are T1-weighted, proton-density weighted, and T2weighted.

Figure 4. (Taken From Reference 9, Figure 1.3): MRI images of the brain: (a) T1-weighted
image; (b) proton-density weighted image; (c) T2-weighted image.
The pictures below were taken from Reference 13.

Figure 5. This
shows nuclei in the
region of the heart,
but imagine it as if
we were focused
on the brain. The
nuclei go into
parallel or antiparallel
arrangement once
B0 is applied (right
picture).

7
These pictures were taken from Reference 13.

Figure 6. A.
shows the
nuclei
precessing as
B0 and Mz are
present.
B. shows
nuclei and their
various phases.

Figure 7. This
shows the Mz as
RF pulses are
administered, as
well as the
induced AC in
the receiver coil.

Figure 8. This
shows the two
types of
relaxation as
they happen to
nuclei. Top
row shows
longitudinal
relaxation and
bottom row
shows
transverse
relaxation.
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Magnetic Resonance Contrast Agents
Magnetic contrast agents shorten relaxation times of water protons to improve contrast in images.
Frullano et al state that current CA’s have the following disadvantages: poor efficiency with regard to
11
shortening of T1 and T2 and lack of specificity. They synthesized MRI probes to detect sialic acid. Most
10
CA’s use gadolinium. However, it is toxic and cannot be injected as is. The ligands should bind it tightly.
10
Ligands currently used form stable Gd3+ chelates.
Some MR CA’s that are currently on the market are listed with with commonly used brand names in
parentheses: In Figure 9a is Gadodiamide (Omniscan); In Figure 9b is Gadopentetate dimeglumine
(Magnevist); Gadoteridol (Prohance) and Gadoversetamide (OptiMark) are not shown.
Louie and workers created MRI CA’s that can indicate reporter gene expression in vivo in opaque
4
animals. Their CA’s function due to effects on the first coordination sphere of the chelated paramagnetic
ion. The access of water into the first coordination sphere is blocked with a substrate that can be removed
by enzymatic cleavage. Following cleavage, the paramagnetic ion interacts with water to increase MR
signal. In reference 4 they report galactopyranose as the blocking group, which makes the CA sensitive to
expression of the commonly used marker gene, beta-galactosidae. Regions of higher intensity in the MR
image correlate with regions expressing the marker enzyme. See Figure 8.
According to Venton and Wightman, after dopamine neuronal activity occurs, changes in blood flow
cause local alkaline pH fluctuations which can interfere with dopamine detection by electroanalytical
5
techniques. Likewise, we have to keep this in mind while developing our MRI probe. MRI CA’s that are
16
pH sensitive have also been synthesized.

Figure 9a Omniscan (http://www.rxlist.com/cgi/generic3/omniscan.htm)

9

Figure 9b Magnevist (http://www.rxlist.com/cgi/generic4/magnevist.htm)

Figure 10. Louie, A. Y.,
Huber, M. M., Ahrens,
E. T., Rothbacher, U.,
Moats, R., Jacobs, R.
E., Fraser, S. E., and
Meade, T. J. Nature
Biotechnology. 2000,
18, 321-325.
A. shows the CA being
activated by beta-GAL.
B. shows the 3-D
model. Purple sphere
is Gd. Picture on right
shows a MR image of
a worm-like embryo
before CA (top) and
after CA (bottom).
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Scheme 1. Imine Formation

Trial #1
A stir bar was put in a round bottom Flask (300 ml or 500 ml), capped with a septum and put under
1
nitrogen gas (inert atmosphere). See Scheme 1. Reagents and solvent (in this trial, EtOAc) were added
with needles and syringes. See Table 1. About 8 minutes after set up the reaction turned cloudy white. It
was left to stir over two nights. It turned a cloudy tan color. TLC silica gel plate was spotted with the
reaction and two starting materials and then developed with 10 ml of 3% methanol in methylene chloride
and 3 drops of ammonium hydroxide. The developed TLC plate was visualized by dipping into a chamber
of potassium permanganate. TLC showed that a reaction had occurred.
Table 1. Reagent Table for Step 1: The Imine Formation
Reagent

Mol. wt./density

Amount

mmol

Equiv.

Ethyl glyoxylate in toluene (50%
w/v solution)
Diethylenetriamine, 98.5%

102.09 g/mol
1.003 g/ml
103.17 g/mol
0.960 g/ml

3.78 ml

18.6

2

1 ml

9.3

1

Ethyl acetate (SOLVENT)

Hazards

120 ml

Proceeded with Step 2, the reductive amination. See Scheme 2. Added a spatula tip full of activated
palladium on carbon (Pd/C) to reaction flask. A balloon purchased from CVS was filled with completely
with hydrogen gas, secured to a syringe and needle; used this to vent reaction flask twice before
beginning hydrogenation where two balloons of hydrogen were allowed to flow into reaction flask. Let stir
for 3 nights. It was observed that the hydrogen balloons deflated after one day. Filtered reaction and took
a TLC with the aforementioned conditions before rotavapping solvent from product. TLC plate showed a
concentrated spot in between the two starting materials’ spots that was presumed to be product.
Rotavapping revealed orange-brown oil. Product was not seen in 1H –NMR spectrum done with 99.6%
Chloroform-d.
H2 (g), Pd/C

C
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H
N

N
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Scheme 2. Reductive Amination.
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Trial #2
Ethyl acetate was seen as a troublesome solvent as it did not yield the expected product. For Trial#2 the
starting materials as listed in Table 1, minus the solvent, were reacted in 120 ml of Methanol instead. The
reaction remained clear and stirred for 3 nights. Much of the methanol evaporated from the, then, amber
colored reaction. A TLC was taken showing that a reaction had occurred. Proceeded with hydrogenation,
which was allowed to stir overnight. Filtered and rotavapped reaction to an amber colored oil. Stored in
chemical refrigerator. Took 1H-NMR spectrum of product in 99.6% Chloroform-d, 4 days later, which
revealed impure sample. Using 6% methanol in methylene chloride as the eluting solvent, ran a
chromatography column with silica gel in attempt to purify the product. Collected 48 fractions in test
tubes. The fractions were spotted and developed on TLC plates in 6% methanol in methylene chloride.
Fractions developed as streaky spots on the TLC plate. Those that developed with a more concentrated
middle spot (assumed to be product) were collected in a clean round bottom flask and rotavapped,
revealing a brown oil. The brown oil was stored under vacuum for 6 days. Collected a GC-MS spectrum
for the oil. The spectrum was not definitive enough to determine which peaks corresponded to our desired
th
product. On the 7 day, ran a second column with 6% methanol in methylene chloride as the solvent with
3 drops of ammonium hydroxide added per 10 ml of solvent. It was theorized that the ammonium
hydroxide might better separation on the column as it did for TLC. Collected fractions. Rotavapped two
sets of fractions. One flask held mostly starting material, the other held mostly product. Collected GC-MS
and 1H-NMR spectra (99.6% Chl-d) for both. The spectra did not show presence of our desired product.
The column was unable to separate the sample, which was labeled “mixture.” Performed Step 3 on
mixture as if it were the desired product to get some experience with setting up Step 3’s reaction and with
hope that our desired product may be isolated later on.

Table 2. Reagent Table for Step 3: Alkylating the Amine
Reagent

Mol. wt./density

Amount

mmol

Equiv.

“Mixture” as if desired
product
Triethylamine (SOLVENT)

275 g/mol

0.45 g

1.63

1

4.93

3

Methylene Chloride
(mixed with Et3N)
t-butyl bromoacetate

1.11 ml
23.7 ml
195.06 g/mol
1.338 g/ml

Methylene chloride (mixed
with t-butyl bromoacetate)

D

0.72 ml
7.4 ml

E

Scheme 3.
Alkylating
the 3 amine
positions

Hazards
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Step 3 was alkylating each of the three amine positions with t-butyl bromoacetate. See Scheme 3.
The N replaces Br where Br is kicked off in an SN2 reaction. The addition of t-butyl bromoacetate was
1
done on a smaller scale than and according to the patent . “Mixture” was dissolved in 1.11 ml of Et3N and
23.7 ml of CH2Cl2. To that we added, dropwise, the 0.72 ml of t-butyl bromoacetate in 7.4ml CH2Cl2, while
stirring. Took a TLC in 6% MeOH in CH2Cl2with 3 drops of NH4OH per 10ml solvent. TLC plate visualized
with UV light then with KMnO4. TLC is not a good way to monitor Step 3 because the t-butyl bromoacetate

12
was not visible to UV light or with KMnO4. The reaction stirred overnight. Took another TLC in same
conditions. A reaction may have occurred due to a slight fade in the top spot. Rotavapped and put under
vacuum for one hour to remove excess solvent. Took 1H NMR (1% TMS Chl-d) which still showed
presence of Et3N. Left under vacuum overnight before doing a workup according to the patent’s
procedure. Dissolved brown oil in 30 ml CH2Cl2. Washed with 55 ml of 0.2N NaOH in a 500ml separatory
funnel. Kept bottom organic layer; discarded upper basic layer. Washed twice with 80 ml distilled water.
Washed with 100ml brine. Dried with MgSO4. Filtered to remove MgSO4. Took 1H NMR (1% TMS Chl-d),
which did not show the presence of our desired product. Trial #2 was discarded.

Trial #3
Two equivalents of ethylglyoxylate and one equivalent of diethylenetriamine were reacted (see Table 1) in
119 ml of MeOH, our third solvent. It was allowed to stir overnight under N2(g). Reaction was tinted light
yellow. TLC was done with the following solvent systems listed in Table 2 in attempt to find an eluting
solvent that will give the Step 1 imine or Step 2 amine a retention factor (Rf) of 0.2-0.4 so that it may be
used to run a column for purification. None of them were better than the old solvent system of 6% MeOH
in CH2Cl2 with 3 drops of NH4OH per 10ml, so we kept that. The TLC showed the disappearance of ethyl
glyoxylate. The imine is assumed to be so polar as to stick to the baseline and therefore is the majority of
the baseline spot. Assuming the imine reaction worked, we proceeded with hydrogenation. This time we
improved the hydrogenation set up. A balloon was attached to a 3-way stopcock with duct tape and filled
with H2 (g). The stopcock was inserted into reaction flask to which a spatula-tip full of Pd/C catalyst had
already been added. The flask was vented with H2 (g) once to clear air out before hydrogenation. Positive
pressure was applied by hooking up the last arm of the stopcock to N2 (g). See Figure 11.

Figure 11. Hydrogenation Set Up. Balloon deflated
slightly after a few hours. Photo by J. Lau.
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Reaction with first balloon stirred overnight for 15 hours. A second balloon of H2 (g) was added and then a
third. Six days after hydrogenation the reaction was filtered to remove Pd/C. DMF has a high boiling point
and cannot be removed from product by rotavapping. To remove it we extracted it several times with
water and EtOAc using a 500ml separatory funnel. The product theoretically was retained in EtOAc layers
and DMF retained in water layers. Rotavapped EtOAc layers to yield a pale yellow oil. A 1H-NMR showed
presence of DMF therefore oil was put on vacuum over two nights to further remove DMF. Another 1HNMR spectrum was collected but our desired Step 2 product, the amine was not present. The oil was
used to try to find TLC conditions for the Step 2 Amine with the hope that if we can find the right solvent
system, we would be able to purify it on a column and then isolate our desired product. TLC plates were
put under vacuum before developing to get rid of DMF from sample spots. See Table 4 for a list of
systems tried but unsuccessful at giving an Rf between 0.2 –0.4 for the amine. Decided not to proceed
with Step 3 since all the 1H NMR spectra thus far from the trials were showing similar junk and lack of
distinctive peaks for our desired products.
Table 3. Unsuccessful TLC solvent systems to
elute Step 1 Imine
1.
2.
3.
4.
5.

DMF
50% DMF in CH2Cl2
70% Benzene, 20% EtOAc, 10% DMF
30% Hexanes in EtOAc
50% EtOAc in hexanes

Trial #4

Table 4. Unsuccessful TLC solvent systems to
elute Step 2 Amine
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.

10% NH4OH in MeOH
3:7 EtOAc/ MeOH
3:7:1 EtOAc/ MeOH/ NH4OH
4:5:1 EtOAc/ MeOH/ NH4OH
8:1:1 EtOAc/ MeOH/ NH4OH
3:7 MeOH/ CH2Cl2
EtOAc
10% NH4OH in EtOAc
5% NH4OH in EtOAc
0.5:0.5:9 NH4OH/ MeOH/ EtOAc
1:0.5:8.5 NH4OH/ MeOH/ EtOAc
2:0.5:7.5 NH4OH/ MeOH/ EtOAc

1

Ethanol was used in the patent as the solvent therefore we tried it for Trial #4. The amount of reagents
used was calculated based on the patent’s scale. See Table 5. Ethyl gyloxylate, diethylenetriamine, and
absolute proof ethanol were added to a 300 ml RB flask by syringe under nitrogen to stir for 2 hours
under heating at 50 degrees Celsius with a water bath. Reaction was removed from heat and 310 mg of
Pd/C catalyst was added for hydrogenation. The reductive amination stirred for 66 hours. Pd/C was
filtered out. Reaction was rotavapped. A 1H-NMR was taken for the imine and amine but did not show
presence of either.
Table 5. Reagent Table for Trial #4
Reagent

Mol. wt./density

Amount

mmol

Equiv.

Ethyl glyoxylate in toluene
(50% w/v solution)
Diethylenetriamine, 98.5%

102.09 g/mol
1.003 g/ml
103.17 g/mol
0.960 g/ml

4.1 ml

20

2.15

1 ml

9.3

1

Ethanol (SOLVENT)

31 ml

10% Pd/C

0.31 g

Hazards

Trial #5
Tried DMF as the solvent again but decreased stir time just in case over-stirring might have negatively
impacted the reaction. Step 1 stirred for 22 hours and Step 2 stirred for 21 hours. 1H-NMR still did not
show presence of desired products.

14

Trial #6
Tried EtOAc as the solvent again as well. Step 1 stirred overnight but reaction precipitated out. An 1HNMR was taken for the rotavapped precipitate to see if imine was in there; however it was not. This
confirmed that EtOAc is not a good solvent for our reaction.

Results
The 6 step, multi-step synthesis for our target molecule has not been completed yet. We were only able
to try steps 1-3. Step 1 did not work despite changing solvent conditions and stir times. Step 2 and 3 are
assumed to be fairly straightforward after successful completion of step 1.

Conclusion
From our lab experience, the best way to monitor our reactions is by taking 1H-NMR spectra. The gas
chromatograph-mass spectrometer (GC-MS) is less effective because we are working with large
molecules, which fragment too much. TLC silica gel plates are not effective for imine reaction monitoring
because they possibly hydrolyze the imines and amines and do not develop well in the many tried solvent
6
conditions. Lee et al recommend Raman spectroscopy for the monitoring of imine synthesis. Most imine
syntheses done are with aryl amines, however, whereas in our case it is not.
We can improve the first step of current synthesis adding an acid catalyst such as H2SO4 or CH3COOH to
facilitate removal of water during imine formation and then heat the reaction to above 150 degrees
Celsius. However, if too much acid is added, the reaction will stop. This is because an amine is a base
and would react with acid to form the ammonium ion. For every amine molecule that does this, the
unshared electron pair has been used to make the N-H bond and is no longer available to act as a
3
nucleophile; it becomes a “benched amine.” It is best to compromise by adding fewer acid molecules than
there are amines. To ensure removal of water add molecular sieves to absorb the water formed, or use a
Dean-Stark trap.
It is best to diversify our strategies for achieving synthesis of this ligand. A different synthesis for same
molecule can be attempted using different starting materials.
Given that dopamine is a challenge to measure, the current state of the art is to utilize Technetium
derivatives to monitor dopamine transporter (DAT) via positron emission tomography (PET) as confirmed
7
by a current study. Perhaps these derivatives can be altered for use as MRI contrast agents instead by
replacing Tc with Gd.
As more lab work occurs, the design of the molecule as well as the corresponding synthetic procedure
should be adjusted accordingly to have the greatest affinity to dopamine, to bind dopamine over other
biological chemicals in the brain, to be safe for injection into humans, to be MRI active, and to be
synthesized via the most efficient and quickest way. Learning about dopamine, its environment in the
brain, and how and when it is produced will help with this process. Finally, it is important to understand
each step of a multi-step synthesis and to engage in troubleshooting along the way in order to progress in
the research.

15
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